Exploring the integration of psychedelic-assisted therapy and digital mental health interventions in trauma recovery for underserved adults with high-functioning autism

Trauma-related disorders and substance use are disproportionately underdiagnosed and undertreated in individuals with High-Functioning Autism (Level 1 Autism Spectrum Disorder), particularly those in underserved or marginalized communities. Emerging evidence suggests that psychedelic-assisted therapies—including psilocybin, MDMA, and ketamine—offer promising outcomes in the treatment of treatment-resistant depression, PTSD, and addiction. Concurrently, digital mental health interventions, such as AI-driven cognitive behavioral therapy (CBT) applications and telepsychiatry platforms, are being expanded to improve behavioral health access among racial/ethnic minorities, rural populations, and Medicaid beneficiaries. However, the intersection of these novel treatment modalities with the unique neuropsychological profiles and care needs of high-functioning autistic individuals remains critically underexplored. This review synthesizes current evidence on the therapeutic potential and limitations of both psychedelic-assisted interventions and digital mental health tools in addressing trauma and addiction recovery in underserved adults with high-functioning autism. The paper explores how trauma manifests uniquely in this population—often masked by compensatory behaviors or misinterpreted as autistic traits—and evaluates the ethical, clinical, and cultural implications of integrating these interventions. Barriers to care, including digital literacy, trial access inequities, and a lack of neurodiversity-informed treatment frameworks, are also examined. The review concludes by proposing a hybrid, culturally responsive, and neurodevelopmentally sensitive care model that leverages digital accessibility and the transformational potential of psychedelics to enhance trauma healing outcomes in high-functioning autistic populations across underserved settings.